stockportfolio.pro
Stocks / DYN vs RCUS
DYN vs RCUS
Dyne Therapeutics, Inc. and Arcus Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Dyne Therapeutics, Inc. (DYN) | Arcus Biosciences, Inc. (RCUS) | |
|---|---|---|
| Market cap | $3.0B | $2.8B |
| Revenue (latest FY) | $0 | $247.00M |
| Net income (latest FY) | $-446.21M | $-353.00M |
| Revenue growth (5y CAGR) | — | 25.9% |
| Net margin | — | -142.9% |
| Return on equity | -45.9% | -55.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DYN — free Open RCUS — freeFrequently asked questions
Which is bigger, DYN or RCUS?
Dyne Therapeutics, Inc. is larger by market capitalization — $3.0B versus $2.8B.
Which grows faster, DYN or RCUS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.